390815-41-5

Usage

Uses

Used in Pharmaceutical Industry:
(R)-1-(3,4-Dimethoxyphenyl)ethanamine hydrochloride is utilized as a therapeutic agent for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. Its mechanism of action involves the modulation of neurotransmitter levels, specifically dopamine and norepinephrine, which helps in managing the symptoms of these conditions.
Used in Central Nervous System Stimulation:
As a central nervous system stimulant, (R)-1-(3,4-Dimethoxyphenyl)ethanamine hydrochloride is employed to enhance cognitive function and alertness. Its psychoactive properties make it a valuable compound in the development of medications aimed at improving focus, attention, and reducing impulsivity in individuals with ADHD.
Used in Treatment of Narcolepsy:
(R)-1-(3,4-Dimethoxyphenyl)ethanamine hydrochloride is also used in the management of narcolepsy, a sleep disorder characterized by excessive daytime sleepiness and sudden episodes of muscle weakness. (R)-1-(3,4-Dimethoxyphenyl)ethanamine hydrochloride's ability to stimulate the central nervous system helps in reducing the frequency and severity of these symptoms, thereby improving the quality of life for those affected by narcolepsy.

Upstream product

• 120-14-9 3,4-dimethoxy-benzaldehyde 
• 906528-66-3 (R_S,S)-(-)-N-[1-(3,4-dimethoxyphenyl)ethyl]-2-methylpropanesulfinamide 
• 937028-41-6 (R_S,R)-(-)-N-[1-(3,4-dimethoxyphenyl)ethyl]-2-methylpropanesulfinamide 
• 1131-62-0 1-(3,4-dimethoxyphenyl)ethanone 
• 820231-38-7 (R)-(-)-N-(3,4-dimethoxybenzylidene)-2-methylpropanesulfinamide 

Relevant academic research and scientific papers

Total synthesis of (R)-(+)-salsolidine by hydride addition to (R)-N-tert-butanesulfinyl ketimine

(R)-(+)-Salsolidine 1 of high enantiomeric purity was synthesized using the Pomeranz-Fritsch-Bobbitt methodology, in which the reduction (NaBH4, DIBAL-H) of N-tert-butanesulfinyl ketimine, derived from 3,4-dimethoxyacetophenone, was the key ste

Co-Catalyzed Synthesis of Primary Amines via Reductive Amination employing Hydrogen under very mild Conditions

Nanostructured and reusable 3d-metal catalysts that operate with high activity and selectivity in important chemical reactions are highly desirable. Here, a cobalt catalyst was developed for the synthesis of primary amines via reductive amination employing hydrogen as the reducing agent and easy-to-handle ammonia, dissolved in water, as the nitrogen source. The catalyst operates under very mild conditions (1.5 mol% catalyst loading, 50 °C and 10 bar H2 pressure) and outperforms commercially available noble metal catalysts (Pd, Pt, Ru, Rh, Ir). A broad scope and a very good functional group tolerance were observed. The key for the high activity seemed to be the used support: an N-doped amorphous carbon material with small and turbostratically disordered graphitic domains, which is microporous with a bimodal size distribution and with basic NH functionalities in the pores.

Chiral Bronsted Acids Catalyze Asymmetric Additions to Substrates that Are Already Protonated: Highly Enantioselective Disulfonimide-Catalyzed Hantzsch Ester Reductions of NH-Imine Hydrochloride Salts

While imines are frequently used substrates in asymmetric Bronsted acid catalysis, their corresponding salts are generally considered unsuitable reaction partners. Such processes are challenging because they require the successful competition of a catalytic amount of a chiral anion with a stoichiometric amount of an achiral one. We now show that enantiopure disulfonimides enable the asymmetric reduction of N-H imine hydrochloride salts using Hantzsch esters as hydrogen source. Our scalable reaction delivers crystalline primary amine salts in great efficiency and enantioselectivity and the discovery suggests potential of this approach in other Bronsted acid catalyzed transformations of achiral iminium salts. Kinetic studies and acidity data suggest a bifunctional catalytic activation mode.

Diastereoselective Pomeranz-Fritsch-Bobbitt synthesis of (S)-(-)-salsolidine using (R)-N-tert-butanesulfinylimine as a substrate

The highly diastereoselective addition of methyl Grignard reagent to chiral (R)-N-tert-butanesulfinylimine 8 was the key step in the synthesis of (S)-(-)-salsolidine 1 of high enantiomeric purity. The resulting addition product, tert-butanesulfinylamide 9

Viral polymerase inhibitors

A compound of the formula I: wherein: X is CH or N; Y is O or S; Z is OH, NH2, NMeR3, NHR3; OR3 or 5- or 6-membered heterocycle, having 1 to 4 heteroatoms selected from 0, N and S, said heterocycle being optionally substituted with from 1 to 4 substituents; A is N, COR7 or CR5, wherein R5 is H, halogen, or (C1-6) alkyl and R7 is H or (C1-6 alkyl), with the proviso that X and A are not both N; R6 is H, halogen, (C1-6 alkyl) or OR7, wherein R7 is H or (C1-6 alkyl); R1 is selected from the group consisting of 5- or 6-membered heterocycle having 1 to 4 heteroatoms selected from O, N, and S, phenyl, phenyl(C1-3)alkyl, (C2-6)alkenyl, phenyl(C2-6)alkenyl, (C3-6)cycloalkyl, (C1-6)alkyl, CF3, 9- or 10-membered heterobicycle having 1 to 4 heteroatoms selected from O, N and S, wherein said heterocycle, phenyl, phenyl(C2-6)alkenyl and phenyl(C1-3)alkyl), alkenyl, cycloalkyl, (C1-6)alkyl, and heterobicycle are all optionally substituted with from 1 to 4 substituents R2 is selected from (C1-6)alkyl, (C3-7)cycloalkyl, (C3-7)cycloalkyl(C1-3)alkyl, (C6-10)bicycloalkyl, adamantyl, phenyl, and pyridyl, all of which is optionally substituted with from1 to 4 substituents; R3 is selected from H, (C1-6)alkyl, (C3-6)cycloalkyl, (C36)cycloalkyl(C1-6)alkyl, (C6-10)aryl, (C6-10)aryl(C1-6)alkyl, (C2-6)alkenyl, (C3-6)cycloalkyl(C2-6)alkenyl, (C6-10)aryl(C2-6)alkenyl, N{(C1-6)alkyl}2, NHCOO(C1-6)alkyl(C6-10)aryl, NHCO(C6-10)aryl, (C1-6)alkyl-5- or 10-atom heterocycle, having 1 to 4 heteroatoms selected from O, N and S, and 5- or 10-atom heterocycle having 1 to 4 heteroatoms selected from O, N and S; wherein said alkyl, cycloalkyl, aryl, alkenyl and heterocycle are all optionally substituted with from 1 to 4 substituents; n is zero or 1; or a detectable derivative or salt thereof. The compounds of the invention may be used as inhibitors of hepatitis C virus replication. The invention further provides a method for treating or preventing hepatitis C virus infection.